Is the new vaccine possible to fight against the cochlea? France and The The Sanofi vaccine will go on sale by the end of 2021, Spain’s method of announcing the first tests for a solution with Iberian colors. The Spanish Agency for Drugs and Health Products (AEMPS) has approved the clinical trial of the PHH-1V vaccine against Govit-19 from Hybra. A statement. “This is the first human test of a vaccine developed in Spain,” he added. Both volunteers participating in the trials will receive the dose at 21-day intervals.
Spanish Prime Minister Pedro Sanchez immediately praised it on Twitter as “a major step in the fight against the epidemic”.
Hybra, Headquartered in Catalonia (northeastern Spain), is expected to produce 400 million doses by 2022 and 1.2 billion by 2023.
It is based on reconstituted proteins and is used in partnership between the US company NovaVox and the French laboratory Sanofi and the British GSK. The corona virus interacts with and infects cells with different types of spikes (viral proteins) on its surface. These proteins can reproduce and then be given to the immune system to react with: it is used in regenerative vaccines such as hepatitis B or papillomavirus.
According to Hebra, the vaccine is available at 2 to 8 C, which facilitates its delivery.